HOME > BUSINESS
BUSINESS
- Bayer Files Eylea for Neovascular Glaucoma
July 29, 2019
- Takeda, Meiji to End Copromotion for Rozerem
July 29, 2019
- Pfizer, Takeda Wind Up Enbrel Copromotion
July 29, 2019
- Chugai Nets 40%-Plus Profit Rise, but Keeps 3-Year EPS Target; President Nixes Avastin Biosame
July 26, 2019
- Opdivo Posts Mixed Results in 1st-Line NSCLC, Scores Win in I/O-I/O Combo
July 26, 2019
- Sumitomo Dainippon to Invest in US Blood Sample Device Startup
July 26, 2019
- EMA Accepts Xtandi for Review in Hormone-Sensitive Prostate Cancer
July 25, 2019
- Novo Files Oral Semaglutide in Japan
July 25, 2019
- Ayumi to Ease Restrictions on Enbrel Biosimilar Use as Product Boost Progresses
July 24, 2019
- HIF-PH Inhibitor Vadadustat Submitted in Japan: Mitsubishi Tanabe
July 24, 2019
- Lenvima/Keytruda Gets FDA’s Breakthrough Status for HCC
July 24, 2019
- Dissolving JV with Takeda, PRA Launches Independent CRO Biz in Japan
July 24, 2019
- Boehringer Said to Consider Nixing Allowances for Some Wholesalers, Denies Intention to Narrow Distributors
July 23, 2019
- Lonasen Effective in Adolescent Japanese Schizophrenia Patients: Sumitomo Dainippon
July 23, 2019
- Nichi-Iko Gets Distribution Rights to Chugai’s Ulcerlmin
July 23, 2019
- Shire’s Vonvendi Filed in Japan
July 23, 2019
- Aspen Japan to Take Over Bristol’s Antiarrhythmic Agent
July 23, 2019
- Ono/BMS, Bayer to Develop Opdivo-Stivarga Combo
July 22, 2019
- Sumitomo Dainippon Offers to Buy Cynata
July 22, 2019
- Nitto Pharma Accelerating Development of Gut Bacteria Drugs, Eyes Clinical Studies within 3 Years
July 22, 2019
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
